Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Retained Earnings (2020 - 2025)

Maxcyte (MXCT) has disclosed Retained Earnings for 6 consecutive years, with -$261.5 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 20.58% to -$261.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$261.5 million through Dec 2025, down 20.58% year-over-year, with the annual reading at -$261.5 million for FY2025, 20.58% down from the prior year.
  • Retained Earnings for Q4 2025 was -$261.5 million at Maxcyte, down from -$251.9 million in the prior quarter.
  • The five-year high for Retained Earnings was -$106.7 million in Q2 2021, with the low at -$261.5 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$172.8 million, with a median of -$170.5 million recorded in 2023.
  • The sharpest move saw Retained Earnings decreased 18.63% in 2022, then fell 28.15% in 2023.
  • Over 5 years, Retained Earnings stood at -$114.3 million in 2021, then decreased by 20.62% to -$137.9 million in 2022, then dropped by 27.51% to -$175.8 million in 2023, then fell by 23.35% to -$216.9 million in 2024, then decreased by 20.58% to -$261.5 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$261.5 million, -$251.9 million, and -$239.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.